research Reversal of andro-genetic alopecia in a male. A spironolactone effect?
A man's baldness improved possibly due to a medication that blocks male hormones.
Search
for
Sort by
Research
780-810 / 1000+ results 
research The efficacy of the combination of topical minoxidil and oral spironolactone compared with the combination of topical minoxidil and oral finasteride in women with androgenic alopecia, female and male hair loss patterns: A blinded randomized clinical trial
Both minoxidil-spironolactone and minoxidil-finasteride treatments work for hair loss, but minoxidil-spironolactone is slightly more effective, especially in women.
research The Serum Evaluation of Sex Hormones Including DHEAs, DHT, Testosterone in Oral Lichen Planus Patients
Oral lichen planus is not linked to sex hormone levels.
research Pharmacological Profile of 9,11-Dehydrocortexolone 17α-Butyrate (CB-03-04), a New Androgen Antagonist with Antigonadotropic Activity
CB-03-04 shows promise as a treatment for prostate issues due to its strong anti-androgen effects.
research 10.51847/1z2Yt2O
SFE is a better extraction method, and the HPTLC method is effective for analyzing wedelolactone in E. alba.
research Topical and intralesional therapies for alopecia areata
Many treatments for alopecia areata have inconsistent results; for under 10s, use minoxidil with a corticosteroid, and for over 10s, add ILC and consider diphenylcyclopropenone for widespread cases.
research ESDR564 – Vertex and Occipital Intermediate and Terminal Hair Follicles from Androgenetic Alopecia Patients are Differentially Affected by Testosterone Ex Vivo
research La combinación de finasteride y doxazosina fue más efectiva que la monoterapia en la hiperplasia prostática benigna
Using finasteride and doxazosina together works better for treating benign prostatic hyperplasia than using just one.
research Treatment of canine Alopecia X with trilostane
Trilostane treatment led to full hair regrowth in most Pomeranians and all miniature poodles with alopecia X.
research Iododerma in pregnancy secondary to iodinated multivitamins
A man developed an allergic skin reaction to a rosacea treatment and improved after stopping the medication and receiving allergy-specific care.
research Spironolactone and breast cancer: Fear not!
Spironolactone does not increase the risk of breast cancer recurrence.
research A randomized, double-blind controlled clinical study to evaluate the efficacy and safety of minoxidil topical 2% nanosuspension with aqueous base in the treatment of androgenetic alopecia areata
The 2% minoxidil nanosuspension is as effective as the commercial product but safer and easier to use.
research Other Products Being Developed by Pharmaceutical and Cosmetic Companies
Minoxidil can cause hair growth as a side effect.
research Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study
CG2001 is safe and well-tolerated for treating hair loss, with fewer side effects than oral finasteride.
research Topical Finasteride versus Topical Spironolactone in the Treatment of Androgenetic Alopecia
Topical spironolactone works better than topical finasteride for hair loss.
research Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis
Finasteride and dutasteride increase sexual dysfunction risk by 1.57 times in male hair loss treatment.
research Клінічний випадок рубцевої алопеції: псевдопелади Брока
Early diagnosis and treatment stopped hair loss and improved the condition.
research ‘Corkscrews’ on the patchy alopecia of a girl
The girl's hair started regrowing after 6 weeks of treatment.
research Relapsing nail fibrokeratoma: A case report on a teenager
Dutasteride is more effective than finasteride for hair growth with similar side effects.
research Mitoxantrone
Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.
research Rapid Hair Regrowth in Localized Alopecia Areata Following Low-Dose Intralesional Corticosteroid
Low-dose intralesional corticosteroid treatment led to rapid hair regrowth in localized alopecia areata.
research NANOCARRIER-BASED DELIVERY OF MINOXIDIL: CURRENT PERSPECTIVES AND FUTURE DIRECTIONS IN ALOPECIA THERAPY
Nanocarrier systems could improve hair loss treatments by delivering drugs more effectively.
research A novel derivative of doxorubicin, AD198, inhibits canine transitional cell carcinoma and osteosarcoma cells in vitro
AD198 is more effective than doxorubicin in stopping certain dog cancer cells.
research S123 The pathological dynamics of androgenetic alopecia and its treatment
Topical spironolactone effectively treats hair loss in women.
research Direct-to-Consumer Teledermatology for Male Androgenetic Alopecia: Narrative Review
Direct-to-consumer teledermatology effectively treats male hair loss but may increase drug costs and requires monitoring for side effects.
research Adverse effects of low-dose oral minoxidil for androgenetic alopecia in 435 patients
Low-dose oral minoxidil may cause side effects like hypertrichosis and is not suitable for everyone.
research Topical Estrogen Therapy for Androgenetic Alopecia in Menopausal Females
Topical estrogen helps hair growth in menopausal women with no major side effects.
research The Requirement to Monitor Low-dose Oral Minoxidil in the Management of Hair Loss
Routine monitoring isn't needed for healthy patients on low-dose oral minoxidil, but is advised for those with kidney issues.
research Tratamentos para Alopécia Androgenética: uma revisão sistemática
Topical Minoxidil 5% is the most effective treatment for hair loss, especially when combined with other treatments.
research Dual Relief: How Atopic Dermatitis Treatments Affect Alopecia Areata—A Small Retrospective Cohort Study
This small retrospective cohort study investigated the effects of atopic dermatitis (AD) treatments on alopecia areata (AA) in 6 patients, revealing that 5 out of 6 patients (83.3%) experienced significant improvements in both conditions after 6 months of treatment with therapies such as JAK inhibitors (baricitinib and upadacitinib), dupilumab, and systemic corticosteroids. The mean Dermatology Life Quality Index (DLQI) score improved by 91.03%, and the mean Severity of Alopecia Tool (SALT) score improved by 95.65%. However, 2 patients experienced worsening AA symptoms with dupilumab, indicating the need for personalized treatment strategies and careful monitoring. The study highlights the potential of JAK inhibitors in managing these comorbid conditions and calls for larger studies to validate these findings.